Background: An osteoporosis drug holiday is recommended for most patients after 3 to 5 years of therapy. Risedronate has a shorter half-life than alendronate, and thus the residual length of fracture protection may be shorter.
Objective: To examine the comparative risks of drug holidays after long-term (≥3 years) risedronate versus alendronate therapy.